INMB
NASDAQ
$1.99
INmune Bio Inc (INMB)
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $7 (+251.76%)
Market Cap
$55M
Free Cash Flow Yield
-36.71%
Beta (5Y)
1.83
Price Chart
Valuation
Market Cap$55M
P/S760.34
P/B2.74
Profitability
Gross Profit (TTM)$50K
EBITDA-$43M
EPS-$1.56
Financial Health
Free Cash Flow Yield-36.71%
Growth & Risk
EPS 5Y CAGR+7.56%
FCF 5Y CAGR+9.22%
Beta (5Y)1.83
Sharpe Ratio0.18